2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER
申请人:[en]OLEMA PHARMACEUTICALS, INC.
公开号:WO2024039861A1
公开(公告)日:2024-02-22
The present disclosure provides 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole derivatives of formula I as estrogen receptor modulators for the treatment of cancer.
[EN] ANTITUMOR COMPOUNDS BASED ON NITROGEN HETEROCYCLES AND USE THEREOF AS MEDICAMENTS<br/>[FR] COMPOSÉS ANTITUMORAUX À BASE D'HÉTÉROCYCLES D'AZOTE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
申请人:[en]FAKULTNI NEMOCNICE HRADEC KRALOVE
公开号:WO2022237922A1
公开(公告)日:2022-11-17
The present invention provides nitrogen heterocyclic compound of general formula I, wherein X is C or N; R1 is selected from C1-C6 alkyls; Z- is –CH2- or –C(O)-; R2 is selected from the group comprising anilino; anilino substituted by di(C1-C6 alkyl)amino group in position 2, 3, or 4; benzylamino; benzylamino substituted by di(C1-C6 alkyl)amino group in position 2, 3, or 4; 4-phenylpiperidin-1-yl, 1-(C1-C6 alkyl)piperazin-4-yl, 1,2,3,4-tetrahydroisoquinolinyl; 1-(C1-C6 alkanesulfonyl)piperazin-4-yl; 4-[4-(C1-C6 alkyl)-piperazin-1-yl]piperidin-1-yl; and pharmaceutically acceptable salts thereof with alkali metals, or addition salts thereof with acids. These compounds are ATR kinase inhibitors, suitable in particular for the treatment of tumor diseases, in monotherapy as well as in combination with another chemotherapeutic or with radiotherapy. (I)